- Conditions
- ASC-US, ASC-H, LSIL
- Interventions
- PVX-2, Placebo
- Biological · Other
- Lead sponsor
- PapiVax Biotech, Inc.
- Other
- Eligibility
- 25 Years to 70 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 6
- States / cities
- Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 118
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Interventions
- pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
- Biological · Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
- Interventions
- Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis, Paclitaxel, pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine
- Drug · Procedure · Other + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A, Orthomyxovirdae, H5N1 Virus
- Interventions
- VRC-AVIDNA036-00-VP
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Leukemia, Lymphocytic, Chronic
- Interventions
- CLL vaccine using DNA plasmid vector
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV Infections
- Interventions
- DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 2,504 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2017
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- HCC
- Interventions
- GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012
- Biological · Device
- Lead sponsor
- Geneos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more
- Conditions
- Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections, Flaviviral Diseases, Flaviviridae Infections, RNA Virus Infections
- Interventions
- VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 15 Years to 35 Years
- Enrollment
- 2,428 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Miami, Florida • Edinburg, Texas • Houston, Texas
- Conditions
- Melanoma (Skin)
- Interventions
- human gp100 plasmid DNA vaccine, mouse gp100 plasmid DNA vaccine
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Melanoma (Skin)
- Interventions
- MKC1106-MT
- Biological
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Los Angeles, California • Boston, Massachusetts + 2 more
- Conditions
- Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A, Orthomyxoviridae, H5N1 Virus
- Interventions
- VRC-AVIDNA036-00-VP
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy
- Interventions
- INO-3401 + EP
- Biological
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Overland Park, Kansas • Rockville, Maryland
- Conditions
- Allergic Rhinitis
- Interventions
- CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control
- Biological · Other
- Lead sponsor
- Immunomic Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Interventions
- pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Paclitaxel, Trastuzumab, Pertuzumab, Docetaxel, Carboplatin, Ultrasound Imaging, Biopsy Procedure, Biospecimen Collection
- Biological · Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- HIV Infections
- Interventions
- p24CE1/2 pDNA vaccine, p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine, Full-length p55^gag pDNA vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Interventions
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Biospecimen Collection
- Biological · Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Healthy
- Interventions
- GLS-5700
- Biological
- Lead sponsor
- GeneOne Life Science, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Miami, Florida • Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- pTVG-HP, Nivolumab, GM-CSF
- Biological · Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
- Interventions
- Vigil, Atezolizumab
- Biological · Drug
- Lead sponsor
- Gradalis, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- Mobile, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more
- Conditions
- Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
- Interventions
- iSCIB1+, Nivolumab & Ipilimumab, Placebo
- Biological · Drug · Other
- Lead sponsor
- Scancell Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- HIV Infections
- Interventions
- EP HIV-1043, EP HIV-1090
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 3
- States / cities
- San Francisco, California • Baltimore, Maryland • Rochester, New York
- Conditions
- Allergic Rhinoconjunctivitis
- Interventions
- CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
- Biological
- Lead sponsor
- Immunomic Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
- Interventions
- Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
- Device · Biological · Other
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 7
- States / cities
- San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more
- Conditions
- Influenza, Human
- Interventions
- Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005, VRC-AViDNA036-00-VP
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland